Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

Recruitment & Eligibility

Inclusion Criteria

diagnosed with stage I-IV ovarian, peritoneal or fallopian tube cancer
completed first-line taxane and platinum-based chemotherapy 1-4 months prior to being enrolled in the study (can be on bevacizumab maintenance)
in remission of their disease at the time of enrollment between 21 and 70 years of age
fluent in English
in the judgment of the consenting professional, have capacity to give consent

Healthy Control Inclusion Criteria:

Exclusion Criteria

active or recurrent disease, or diagnosis of another cancer (except basal cell carcinoma) as per medical records at the time of enrollment
exposure to chemotherapy or radiation therapy for any medical condition unrelated to ovarian cancer
on hormonal therapy at the time of enrollment
neurological disorder or moderate to severe head trauma (loss of consciousness > 60 min)
neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.
self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia
unable to complete cognitive tests
with standard contraindications to MRI examinations

Healthy Control Exclusion Criteria:

exposure to chemotherapy or radiation therapy for any medical condition
on hormone replacement therapy at the time of enrollment
neurological disorder or moderate to severe head trauma (loss of consciousness > 60 min)
neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.

Study & Design

Arm && Interventions

Group	Intervention	Description
healthy controls	Neuroimaging & Neuropsychological Evaluation	-
diagnosed with ovarian that recieved chemo	Neuroimaging & Neuropsychological Evaluation	-

Primary Outcome Measures

Name	Time	Method
alterations in regional brain volume	1 year	will undergo structural MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Three to five T1 weighted sagittal slices are collected to localize the anterior and posterior commissures. Functional imaging: Blood Oxygenation Level-Dependent (BOLD) contrast imaging, which reflects changes in venous deoxyhemoglobin associated with neuronal activity, will be used.
dorsolateral prefrontal cortex	1 year	will undergo functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus.Three to five T1 weighted sagittal slices are collected to localize the anterior and posterior commissures. Functional imaging: Blood Oxygenation Level-Dependent (BOLD) contrast imaging, which reflects changes in venous deoxyhemoglobin associated with neuronal activity, will be used.

Secondary Outcome Measures

Name	Time	Method
neuropsychological functions	1 year	Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC. All subjects will undergo a neuropsychological evaluation including standardized tests of attention and working memory, executive functions, and memory considering that these domains have been shown to be particularly sensitive to cancer treatment-induced cognitive dysfunction.

Recruitment & Eligibility